NCT04226612 Association of Inpatient Blood Pressure Levels With In-hospital Adverse Events(APPLE Study)
| NCT ID | NCT04226612 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Blood Pressure |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2000-01-01 |
| Primary Completion | 2019-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2000-01-01 with a primary completion date of 2019-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to investigate the association between inpatient blood pressure levels and in-hosopital adverse outcomes.
Eligibility Criteria
Inclusion Criteria: * Inpatient with all age or race; * Have blood pressure data. Exclusion Criteria: * Non-patients； * Death outside the hospital； * Missing blood pressure data.
Contact & Investigator
Feng Ying-qing, PhD
STUDY DIRECTOR
Guangdong Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT04226612 clinical trial?
This trial is open to participants of all sexes, studying Blood Pressure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04226612 currently recruiting?
Yes, NCT04226612 is actively recruiting participants. Contact the research team at 651792209@qq.com for enrollment information.
Where is the NCT04226612 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT04226612 clinical trial?
NCT04226612 is sponsored by Guangdong Provincial People's Hospital. The principal investigator is Feng Ying-qing, PhD at Guangdong Provincial People's Hospital. The trial plans to enroll 100,000 participants.